Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

First participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.

Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/202.

NEW YORK, USA, and MAINZ, Germany, May 5, 2020 – Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

Read More
Back to News